Mr. Michael McFadden reports

ALPHA COGNITION RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION COVERING USE OF ALPHA-1062 FOR MILD TO MODERATE ALZHEIMER'S DISEASE

The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for Alpha Cognition Inc.'s patent application No. 17/575,025, titled "Solid Forms of Alpha-1062 Gluconate," which includes claims covering protection for crystalline solid forms of Alpha-1062 and will bolster existing patents that the company holds. A notice of allowance is issued after the USPTO makes the determination that a patent should be granted from an application.

This notice of allowance signifies a pivotal step forward in the company's journey and is the result of years of relentless research and development, conducted by Alpha Cognition's team of esteemed scientists, researchers and medical experts. Alpha-1062 represents a breakthrough in the neurology market, offering a novel approach to addressing the symptomatic treatment of Alzheimer's disease.

"We are pleased by the progress we have made in the United States Patent and Trademark Office which underscores the innovative nature of Alpha-1062 for the symptomatic treatment of mild-to-moderate Alzheimer's disease. This patent will provide protection through 2042 in the United States and will allow our team to continue to build on the immense potential that Alpha-1062 holds for patients and healthcare providers," stated Alpha Cognition's chief executive officer, Michael McFadden.

About Alpha Cognition Inc.

Alpha Cognition is a clinical-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive impairment with mild traumatic brain injury, for which there are currently no approved treatment options.

Alpha-1062 is a patented new chemical entity being developed as a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. Alpha-1062's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Alpha-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for cognitive impairment with mTBI.

We seek Safe Harbor.